Hims & Hers Health (NYSE:HIMS) Shares Down 1.1% - What's Next?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded down 1.1% on Tuesday . The stock traded as low as $56.06 and last traded at $56.15. 62,498,902 shares traded hands during mid-day trading, an increase of 212% from the average session volume of 20,007,452 shares. The stock had previously closed at $56.77.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Truist Financial decreased their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Leerink Partners boosted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Finally, Bank of America boosted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Price Performance

The company has a market cap of $12.04 billion, a PE ratio of 122.23 and a beta of 2.09. The business has a 50-day moving average of $41.26 and a 200 day moving average of $36.68.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the previous year, the company posted $0.05 earnings per share. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the transaction, the chief executive officer now owns 173,655 shares of the company's stock, valued at $5,900,796.90. This represents a 42.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 3,236 shares of the company's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $27.77, for a total value of $89,863.72. Following the completion of the transaction, the insider now directly owns 170,285 shares of the company's stock, valued at approximately $4,728,814.45. This trade represents a 1.86% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 617,367 shares of company stock valued at $25,227,888. Company insiders own 13.71% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares during the period. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.